Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants

Pediatr Infect Dis J. 2008 Jan;27(1):71-3. doi: 10.1097/INF.0b013e318159228f.

Abstract

We report the phase III trial efficacy of 7-valent pneumococcal conjugate vaccine against clinical and culture proven otitis media (OM) among Navajo and White Mountain Apache infants. Efficacy was -0.4% (95% CI: -19.4 to 15.6) for clinically-diagnosed OM, 5.1% (95% CI: -51.5 to 40.6) for severe OM, and 64% (95% CI: -34% to 90%) for vaccine serotype pneumococcal OM suggesting that this vaccine is efficacious for pneumococcal OM in this high risk population.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Heptavalent Pneumococcal Conjugate Vaccine
  • Humans
  • Indians, North American*
  • Infant
  • Meningococcal Vaccines / immunology*
  • Meningococcal Vaccines / therapeutic use
  • Otitis Media / immunology
  • Otitis Media / therapy*
  • Pneumococcal Infections / immunology*
  • Pneumococcal Infections / therapy*
  • Pneumococcal Vaccines / immunology*
  • Pneumococcal Vaccines / therapeutic use
  • United States

Substances

  • Heptavalent Pneumococcal Conjugate Vaccine
  • Meningococcal Vaccines
  • Pneumococcal Vaccines